$ cat ./records/gates-foundation-awards-9-million-to-institut-pasteur-gbf-consort-2005.txt
Gates Foundation Awards $9 Million to Institut Pasteur–GBF Consortium for Hepatitis C and HIV Vaccine Research
[RECORD.TXT] · cat --full
The Gates Foundation awarded $9 million to a research consortium led by Germany's GBF and the Institut Pasteur in Paris for hepatitis C and HIV vaccine development, selected from more than 1,500 applications across 75 countries in the Grand Challenges in Global Health competition. The project used humanised mouse models to study HCV infection and vaccine-mediated immune responses. This was among the foundation's earliest investments in hepatitis C vaccine science for a disease affecting 58 million people globally for which no vaccine yet exists.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants $6 Million to HarvestPlus to Introduce Vitamin A Orange-Fleshed Sweet Potato in East Africa
Next →
Gates Foundation Commits $75 Million to Target Malaria CRISPR Gene Drive Research Program
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.